Exxel Pharma Provides Business Overview and Upcoming Milestones
Company advancing innovative, small molecule for treatment of refractory chronic cough where there are currently no FDA-approved therapies Lead program, EX937, initially targeting a $11B global market with potential to expand into multiple high-value i…